key: cord-0918493-61krxh4h
authors: Hsu, Caroline M.; Gupta, Shruti; Tighiouart, Hocine; Goyal, Nitender; Faugno, Anthony J.; Tariq, Asma; Raichoudhury, Ritesh; Sharma, Jill H.; Meyer, Leah; Kshirsagar, Ravi K.; Jose, Aju; Leaf, David E.; Weiner, Daniel E.
title: Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study
date: 2021-12-04
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2021.11.004
sha: 2bdabb15724c888658bcda93f30313377d1ab983
doc_id: 918493
cord_uid: 61krxh4h

RATIONALE & OBJECTIVE: Acute kidney injury treated with kidney replacement therapy (AKI-KRT) occurs frequently in critically ill patients with COVID-19. We examined the clinical factors that determine kidney recovery in this population. STUDY DESIGN: Multicenter cohort study. SETTING & PARTICIPANTS: 4221 adults with COVID-19 not receiving kidney replacement therapy who were admitted to intensive care units at 68 US hospitals with COVID-19 from March 1 to June 22, 2020 (the “ICU cohort”). Among these, 876 developed AKI-KRT after admission to the ICU (the “AKI-KRT subcohort”). EXPOSURE(S): The ICU cohort was analyzed using AKI severity as the exposure. For the AKI-KRT subcohort, exposures included demographics, comorbidities, initial mode of KRT, and markers of illness severity at the time of dialysis initiation. OUTCOME(S): The outcome for the ICU cohort was estimated glomerular filtration rate (GFR) at hospital discharge. A three-level outcome including death, kidney nonrecovery, and kidney recovery at discharge, was analyzed for the AKI-KRT subcohort. ANALYTICAL APPROACH: The ICU cohort was characterized using descriptive analyses. The AKI-KRT subcohort was characterized with both descriptive analyses and multinomial logistic regression to assess factors associated with kidney nonrecovery while accounting for death. RESULTS: Among a total of 4221 patients in the ICU cohort, 2361 (56%) developed AKI, including 876 (21%) who received KRT. More severe AKI was associated with higher mortality. Among survivors, more severe AKI was associated with an increased rate of kidney nonrecovery and lower kidney function at discharge. Among the 876 patients with AKI-KRT, 588 (67%) died, 95 (11%) had kidney nonrecovery, and 193 (22%) had kidney recovery by the time of discharge. The odds of kidney nonrecovery was greater for lower estimated GFR with odds ratios (ORs) of 2.09 (95% CI, 1.09-4.04), 4.27 (95% CI, 1.99-9.17), and 8.69 (95% CI, 3.07-24.55) for CKD GFR categories 3, 4, and 5, respectively, compared to estimated GFR > 60 mL/min/1.73 m2. Oliguria at the time of KRT initiation was also associated with nonrecovery (OR 2.10 [95% CI, 1.14-3.88] and 4.02 [95% CI, 1.72-9.39] for patients with 50-499 and <50 mL urine/day respectively, compared to ≥500 mL urine/day). LIMITATIONS: Later recovery events may not have been captured due to lack of post-discharge follow-up. CONCLUSIONS: Lower baseline eGFR and reduced urine output at the time of KRT initiation are each strongly and independently associated with kidney nonrecovery among critically ill patients with COVID-19.

Acute kidney injury (AKI) occurs frequently in patients with coronavirus disease 2019 (COVID- 19) , affecting 17 to 46% of hospitalized patients, 14% to 20% of whom are treated with kidney replacement therapy (KRT). [1] [2] [3] [4] Dialysis is resource-intensive, and long-term dialysis dependence impacts patients' quality of life and other clinically important outcomes. [5] [6] [7] Furthermore, studies have demonstrated high mortality among critically ill patients with COVID-19 who require dialysis for AKI. 1, 8 Accurate prognostication of both long-term dialysis dependence and mortality therefore has key implications for clinical outcomes and quality of life, and may affect decision-making in the setting of critical illness and AKI.

At this time, no widely accepted tools exist for prognostication of kidney recovery from AKI, particularly AKI-KRT. Mortality as a competing outcome has been historically difficult to account for. 9, 10 Studies of kidney recovery have been further limited by variation in recovery patterns and lack of detailed data on clinical status at the time of AKI or of KRT initiation. [9] [10] [11] In comparison, AKI associated with COVID-19, though occurring via multiple possible mechanisms, 12 has less heterogeneity with respect to timing and underlying cause; thus, a pattern for recovery may be discernable.

Using detailed clinical data from a large multicenter cohort of critically ill patients with COVID- 19 , we first investigated the association of AKI severity with kidney function at the time of hospital discharge. Next, among patients with AKI-KRT, we examined the clinical factors which may predict kidney recovery, using baseline characteristics and measures of clinical status at the time of dialysis initiation.

We used data from the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 (STOP-COVID), a multicenter cohort study that enrolled consecutive adults (≥18 years old) with laboratory-confirmed COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the United States. We included patients admitted to ICUs between March 1 and June 22, 2020. This study was approved by the institutional review boards at all participating sites with a waiver of informed consent. All data except dates were deidentified.

Study personnel at each site collected data by detailed chart review using a standardized electronic case report form via a secure Research Electronic Data Capture (REDCap) database.

Patient-level data included baseline information on demographics, coexisting conditions, symptoms, medications before hospital admission, and vital signs on ICU admission; daily data for the 14 days after ICU admission on physiologic and laboratory values, medications, nonmedication treatments, and organ support; and outcomes data on discharge and death, including kidney function at discharge. Additional details regarding the STOP-COVID parent study are reported elsewhere. 8, 13 

Initial analyses evaluated the entire STOP-COVID population, excluding those with dialysis dependence at hospital admission, those without outcome data, those still hospitalized at last follow-up, those without kidney function assessment at discharge, and those without a baseline serum creatinine; these patients composed the ICU cohort. These descriptive analyses examined kidney outcomes and mortality by severity of AKI. Baseline serum creatinine (SCr) was defined as the lowest of three values: 1) lowest pre-admission SCr value between 7 and 365 days prior to admission; 2) SCr on hospital admission; and 3) SCr on ICU Day 1. AKI severity was determined by calculating the ratio of the peak SCr in the first 14 days after ICU admission relative to the baseline value, using thresholds defined by KDIGO AKI staging. 14 J o u r n a l P r e -p r o o f Similarly, among survivors, the ratio of the discharge SCr to the baseline, as well as dialysis dependence at discharge, was used to categorize kidney recovery. Mortality was defined by vital status at hospital discharge. Outcomes were compared by AKI severity.

Further analysis focused on the subset of patients who received dialysis during the first 14 days after ICU admission, termed the AKI-KRT subcohort. KRT Day 1 was defined as a patient's first day of dialysis.

Exposures of interest identified a priori based on clinical importance and availability in the dataset were demographics (age, sex, race, ethnicity), baseline medical status (history of diabetes mellitus, CKD stage derived from baseline estimated glomerular filtration rate [eGFR] using the CKD-EPI equation with a race coefficient), 15 initial mode of dialysis (continuous kidney replacement therapy, intermittent hemodialysis, or peritoneal dialysis), markers of illness severity on KRT Day 1 (serum albumin, arterial pH, 24-hour urine output, maximum number of vasopressors or inotropes received that day), and occurrence of a major cardiac event (ventricular tachycardia, ventricular fibrillation, or cardiac arrest) on or preceding KRT Day 1.

Patients were followed until either hospital discharge or death. Kidney recovery was defined as independence from dialysis at discharge. The date of recovery was the date of last dialysis; if it could not be determined (since daily data on KRT dependence were only collected for the first 14 days following ICU admission and on hospital discharge), it was set as the date of discharge (see Supplement section S2 for details). Among survivors discharged with recovery, SCr at the J o u r n a l P r e -p r o o f time of discharge was used to calculate discharge eGFR, which was then compared to baseline eGFR in a series of descriptive analyses.

Several regression methods were used to assess predictors of recovery while accounting for hospital mortality. These regression analyses were applied to the same group of patients, the AKI-KRT subcohort, to assess for consistency in results. Missing exposure variables were imputed using methods described in the Supplement section S2.

Primary analyses used multinomial logistic regression to associate covariates of interest with the outcome of kidney recovery, using kidney nonrecovery as the reference outcome and death as an alternate outcome.

Two secondary analyses were conducted. First, ordinal logistic regression analysis was performed to associate covariates with the composite outcome of kidney nonrecovery or death, and with the outcome of death alone, thus treating death as the least desirable outcome, followed by kidney nonrecovery, with kidney recovery as the most desirable outcome. Second, because logistic regression does not account for differences in follow-up time, instead assuming the same follow-up time for all patients, cause-specific time-to-recovery analysis was used to assess the instantaneous rate of recovery, treating death as a competing event. (Time-torecovery was not used for primary analysis due to uncertainty around the date of recovery, with most patients' recovery status being reported only at hospital discharge.) Those who were discharged without kidney recovery were censored at the time of discharge.

For each of these three approaches, three sets of analyses were conducted: 1) primary analyses utilized all a priori specified exposure variables; 2) parsimonious analyses only Statistical analyses were performed with SAS EG v7.14 (SAS Institute, Cary, NC).

Among 5154 patients enrolled in STOP-COVID, 741 had incomplete data reporting and 192 were receiving maintenance dialysis at admission; therefore 4221 patients comprised the ICU cohort ( Figure 1 ). Of these, 2681 (63%) were male and the mean age was 61 ± 15 [SD] years; 1085 (26%) had baseline eGFR less than 60 mL/min/1.73m 2 ( Table 1) .

Within the first 14 days after ICU admission, 2361 patients (56%) developed AKI, including 527 (12%) with stage 1, 468 (11%) with stage 2, 490 (12%) with stage 3 without KRT, and 876 (21%) who received KRT (Figure 1 ). More severe AKI was associated with greater mortality; among those with no AKI, stage 1 AKI, stage 2 AKI, stage 3 AKI without KRT, and AKI-KRT, 26%, 44%, 60%, 73%, and 67% died, respectively (Figure 2) . 11% of those with AKI-KRT were discharged with dialysis. Discharge with dialysis occurred in less than 0.5% of patients with other stages of AKI; since, in this study, AKI stage was defined by its peak severity within the first 14 days of ICU admission, these patients must have received KRT beginning after the first 14 days of ICU admission. Among survivors, more severe AKI was associated with higher likelihood of kidney nonrecovery at discharge, as well as higher SCr at discharge. Among those with no AKI, stage 1 AKI, stage 2 AKI, stage 3 AKI without KRT, and AKI-KRT, 1%, 7%, 11%, J o u r n a l P r e -p r o o f 41%, and 52% had a discharge SCr ≥1.5 times their baseline SCr or remained KRT-dependent at discharge (Figure 3) .

Among the 876 patients with AKI-KRT, mean age was 61 ± 12 [ Table 2) .

Of the 876 patients with AKI-KRT, 588 (67%) died, 95 (11%) were discharged alive and remained dialysis-dependent at discharge, and 193 (22%) had recovery by the time of discharge. In multinomial logistic regression models, lower baseline kidney function and lower urine output on KRT day 1 were each associated with nonrecovery ( Figure 4) . The odds of nonrecovery approximately doubled with each successive stage of CKD, with odds ratios of 2.09 (95% CI, 1.09-4.04), 4.27 (95% CI, 1.99-9.17), and 8.69 (95% CI, 3.07-24.55) for patients with CKD stages 3, 4, and 5, respectively, compared to patients without CKD. Compared to patients with urine output ≥500 mL per day, oliguria (urine output 50-499 mL per day) was associated with a 2.10-fold increased odds of nonrecovery (95% CI, 1.14-3.88) and anuria J o u r n a l P r e -p r o o f (urine output <50mL per day) was associated with a 4.02-fold increased odds of nonrecovery (95% CI, 1.72-9.39) (Figure 4, Table S1 ). A descriptive analysis of survivors also showed the association of both lower baseline kidney function and lower urine output with kidney nonrecovery (Figure 5 ). Of note, those who died had much shorter follow-up time (median 7 [IQR: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] days) compared to those who either had kidney recovery (31 days) or kidney non-recovery (30 [21-42.5] ), limiting interpretation of predictors of mortality.

Results were similar in secondary analyses utilizing ordinal logistic regression: Older age, baseline eGFR ≤15 mL/min/1.73m 2 , lower arterial pH, and lower urine output were each associated with the composite outcome of nonrecovery or death, and older age, non-Black race, initiation with non-CKRT modality, lower albumin, lower arterial pH, anuria, need for two or more vasopressors/inotropes, and a preceding major cardiac event were each associated with mortality alone (Table S2) . Cause-specific time-to-recovery analysis that treated death as a competing event identified Black race, baseline eGFR >15 mL/min/1.73m 2 , and greater urine output as associated with a higher likelihood of recovery (Table S3) . Parsimonious and expanded analyses did not yield notably different results, though effect sizes were somewhat increased in parsimonious models (Tables S1-S3).

Among the 288 patients with AKI-KRT who survived to discharge, 162 (56.2%), 64 (22%), 40(14%), and 22 (8%) had initial eGFR of greater than 60, 31-60, 16-30, and ≤15 mL/min/1.73m 2 respectively. 95 patients (33%) were dialysis dependent at discharge. Lower baseline eGFR and oligoanuria (urine output <500 mL per day) on the day of KRT initiation were each associated with a higher likelihood of nonrecovery (Figure 6 ). Individuals with higher baseline GFR were more likely to have recovery of kidney function to an eGFR of ≥60 mL/min/1.73m 2 at discharge (Figure 7 ).

In this multicenter cohort study of 4221 critically ill patients with COVID-19 admitted to ICUs at 68 US hospitals, we identified several noteworthy findings regarding outcomes in patients with AKI. First, greater AKI severity was associated with higher in-hospital mortality and, among survivors, worse kidney function at discharge. Second, among patients who had AKI and were treated with KRT, almost two-thirds died. Of those who survived to discharge, approximately two-thirds recovered kidney function and were discharged without dialysis dependence. Third, across multiple analyses, lower baseline GFR and oligoanuria at dialysis initiation were each associated with lower likelihood of recovery from AKI-KRT.

Detailed study of kidney recovery among patients with COVID-19 with AKI-KRT has been limited. A single-center study in New York City from approximately the same time period as the current report found that, of 347 patients hospitalized with COVID-19 who developed AKI-KRT, only 87 (25%) survived to discharge; 1 among those who survived, 70% were discharged without dialysis, findings that are comparable to our results. A small study in Berlin, Germany from the same time period reported the outcomes of 74 patients with COVID-19 admitted to an ICU who developed AKI-KRT. 16 Compared to our study, fewer patients had CKD, which may account for Since this study was conducted, COVID-19 management has evolved to include the greater use of corticosteroids and other immunomodulatory agents (e.g. tocilizumab) in patients with severe illness, as these agents have been demonstrated to have a beneficial effect on patient survival. 17, 18 In contrast, our results showed steroids to be associated with greater mortality, perhaps indicating that, during this phase, they were selectively administered to those with more severe illness (Supplemental Table S1 ). Interestingly, the same analysis suggested an association between steroid use and kidney recovery, though it did not reach statistical significance, and in a separate recent study, steroid use was associated with reduced risk for AKI progression. 19 The observed association of steroid use with better kidney outcomes should be more systematically explored in subsequent larger clinical/epidemiologic investigations.

Tocilizumab and remdesivir, which are also both now used more widely than during the study period, were not significantly associated with either kidney or mortality outcomes in this study.

Compared to prior studies of AKI-KRT among critically ill patients without COVID-19, this study and other studies of patients with COVID-19 have found higher rates of in-hospital mortality and of dialysis dependence at hospital discharge. 1, 8, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] These differences in outcomes may reflect the profound multiorgan failure associated with COVID-19 during the initial spring 2020 surge.

The higher rate of kidney non-recovery may also be due to direct infection of the kidneys by the SARS-CoV-2 virus, though this remains controversial. [29] [30] [31] Moreover, many of the studies conducted on AKI among patients with COVID-19, including this study, have been conducted in academic hospitals, which tend to experience a higher acuity of disease. Nevertheless, despite variation in the rates of each outcome in the present study as compared with prior research in non-COVID-19 settings, the predictors of kidney recovery identified in the current study were similar to those found in studies among critically ill patients without COVID-19.

The association of both lower baseline eGFR and oliguria at the time of KRT initiation with a lower likelihood of kidney recovery highlights that kidney recovery after AKI is dependent on both the pre-injury level of kidney function as well as the severity of the injury itself. Both elements of this conceptual model have been noted in other studies of recovery from AKI.

Multiple studies have associated lower kidney function prior to an AKI episode with a higher likelihood of ongoing dialysis dependence or later CKD progression. 25, 28, 32, 33 Of note, most of these studies were conducted in hospitalized patients without either a specified mechanism of AKI or a unifying underlying diagnosis, unlike this study which included only COVID-19 patients admitted to an ICU. Direct comparison of effect sizes is limited, however, by variation in outcome assessments. Other clinical predictors of kidney recovery have not been studied extensively. A prior prospective cohort study of ICU patients with AKI-KRT similarly noted an association between oliguria and dialysis dependence, with recovery assessed at one year. 25 This work has considerable implications for clinical care, both during and following the COVID-19 pandemic. The magnitude of the effect sizes found in our models is striking. One may consider an example of comparing a patient with more than 500 mL of urine output at the time of dialysis initiation with a patient with anuria (less than 50 mL). Based on our findings, the odds of survival for the patient with normal urine output are 2.3 times higher than those of the patient with anuria, and his/her odds of kidney recovery are more than 4-fold increased. Compared to a patient with both anuria and eGFR of ≤15, a patient with neither condition has a 1.9-fold greater odds of survival, and an almost 13-fold greater odds of kidney recovery. That a baseline eGFR ≤15 appears to confer some survival benefit may reflect earlier ICU admission and dialysis initiation for less severe illness in these patients with advanced CKD.

Accurate prognostication of outcomes can assist clinical decision-making when dialysis initiation is being considered for AKI. While nephrologists often use a "wait and see" approach in such We also acknowledge several limitations. First, SCr and KRT data were only collected for the first 14 days following ICU admission and on hospital discharge, and as a result, outcomes were most reliably assessed at discharge. Logistic regression analysis was chosen to reflect this outcome assessment, but it assumes similar follow-up time among patients. Therefore, associations of exposures with mortality may have been biased by less follow-up time, though, given the overall short follow-up time for all patients, this bias is likely minimal, and similar results in time-to-event sensitivity analysis are reassuring. In addition, the uncertain timing of kidney recovery in some patients creates a bias toward the null in the time-to-recovery analysis.

Furthermore, lack of post-discharge follow-up data precluded analysis of kidney recovery occurring post-discharge, thus potentially underestimating kidney recovery rates. Reasons for KRT initiation were not captured. We were unable to determine how many deaths occurred after transfer to conservative management, which may partially account for the greater mortality rate observed among those with Stage 3 AKI without KRT than those with AKI-KRT. Lastly, addressing death as a competing outcome is always a challenge in studies of AKI-KRT outcomes, and the high mortality rate in this dataset likewise limits conclusions.

In summary, in this large cohort study of critically ill patients with COVID-19, CKD and oliguria at the time of dialysis initiation were each significantly associated with a lower likelihood of kidney recovery. The magnitude of the associations presented here may assist prognostication of longterm dialysis dependence, which carries implications for patients' physical health and quality of life. Age is displayed as mean ± SD. Serum albumin and arterial pH are displayed as median [IQR] . All other data are displayed as frequency (%). eGFR, estimated glomerular filtration rate; ICU, intensive care unit; UOP, urine output 

Kings County Hospital Center

New York-Presbyterian Queens Hospital: Akshay Athreya, Mohamed Farag

Brigham and Women's Faulkner Hospital, Massachusetts General Hospital

Hospital: Jingjing Zhang*, Sang Hoon Woo, Xiaoying Deng

United Health Services Hospitals: Muhammad Imran Ali

Authors' contributions: Research idea and study design: CMH & SG (equal contribution

Support: CMH is supported by the American Society of Nephrology KidneyCure Foundation's Ben J. Lipps Research Fellowship. SG receives funding from GE Healthcare and is a scientific coordinator for GlaxoSmithKline's ASCEND study. DEL is supported by NIH grants R01HL144566 and R01DK125786. These funders did not have a role in study design, data collection, analysis, reporting, or the decision to submit for publication. Financial Disclosure: The authors declare that they have no other relevant financial interests

AKI in Hospitalized Patients with COVID-19

Acute kidney injury in patients hospitalized with COVID-19

The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis

Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis

US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States

Intensive Hemodialysis and Health-Related Quality of Life

Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study

Mortality and Recovery Associated with Kidney Failure due to Acute Kidney Injury

Recovery after Acute Kidney Injury

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

KDIGO Clinical Practice Guideline for Acute Kidney Injury

A new equation to estimate glomerular filtration rate

High rates of long-term renal recovery in survivors of coronavirus disease 2019-associated acute kidney injury requiring kidney replacement therapy

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Drug treatments for covid-19: living systematic review and network meta-analysis

Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study

Clinical profile and outcomes of COVID-19 patients with acute kidney injury: a tertiary centre experience from South India

Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury

Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness

Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19

Renal Replacement Therapy Modality in the ICU and Renal Recovery at Hospital Discharge

Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study

Five-year outcomes of severe acute kidney injury requiring renal replacement therapy

Long-term prognosis after acute kidney injury requiring renal replacement therapy

Nonrecovery of kidney function and death after acute on chronic renal failure

The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study

Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19

Does SARS-CoV-2 Infect the Kidney?

Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease

Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury

Clinical Practice Guideline. Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis

The Role of Time-Limited Trials in Dialysis Decision Making in Critically Ill Patients

All other data are displayed as frequency (%). CKRT, continuous kidney replacement therapy; eGFR, estimated glomerular filtration rate; iHD

KRT, kidney replacement therapy